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adherent patients were younger (20.9 vs. 25.8 years old, p= 0.011). The adjusted rate 
of thalassemia-related outpatient visits PPPM was higher in adherent patients (aIRR: 
1.11, p= 0.004). However, adherent patients incurred fewer thalassemia-related hos-
pitalizations (0.80, p= 0.002) and ER visits (0.64, p< 0.001). PPPM thalassemia-related 
medical costs followed a similar trend with slightly higher outpatient costs (aCD: 
$113, p= 0.504) and lower total costs (aCD: -$1,922, p= 0.056), mainly driven by lower 
inpatient costs (aCD: -$2,504, p= 0.052). Similar results were observed for all-cause 
RU and medical costs. While all-cause pharmacy costs were higher in adherent 
patients (aCD: $1,506, p< 0.001), non-ICT pharmacy costs was slightly lower (-$234, 
p= 0.200). CONCLUSIONS: This study shows that thalassemia patients adherent to 
ICT incurred more outpatient visits, which may be related to better disease moni-
toring and management, potentially resulting in the lower rates of acute care visits 
and related costs observed in this cohort. Enhanced adherence to ICT may reduce 
downstream costs associated with acute care, thereby reducing the financial burden 
of thalassemia from a payer’s perspective.
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OBJECTIVES: CDC has classified prescription drug abuse an epidemic with sig-
nificant societal economic burden. A 2009 systematic review on economic burden 
of prescription opioid misuse and abuse (POMA) found total cost (US, 2001) was 
~$8.6 billion and abusers’ annual medical costs were ~$14,000 higher than nona-
busers. The objective of this research was to update and synthesize all evidence 
around prevalence and costs of opioid abuse. METHODS: A systematic review was 
conducted to update the 2009 results by reviewing worldwide literature involving 
humans published in English from 2009-2014. The primary focus was prevalence 
and cost of POMA. Sources included PubMed, Embase, OpenSIGLE (for gray literature) 
and others. RESULTS: 5,281 citations were identified and 505 selected for inclusion; 
297 prevalence, 38 cost, 17 cost+prevalence, 124 consequences/sequelae, and 29 
other. CASP checklists were completed for 21 papers prioritized for further review; 
cost alone and cost+prevalence were included for final review. POMA prevalence 
ranged from 1.6 – 2.66/1000 in US privately insured and 5.0 – 8.7/1000 in Medicaid. 
5 year VA prevalence was 11.1/1000. Prevalence in the US increased from 1.8/1,000 
to 5.0/1,000 in Florida Medicaid and 0.5/1,000 to 1.6/1,000 in commercially insured 
from 1999-2006. Global illicit opioid dependence rate was 2.2/1000. Total US societal 
costs of POMA were $53.4 -$57.7 billion. Prescription opioid poisoning accounted for 
$15.9 billion. Excess annual medical costs in commercial claims data for patients 
with diagnosed opioid abuse and dependence was $9,456-$20,546. Similar results 
were seen in Medicaid and the VA which were ~$15,000. The per event cost for opioid 
abuse related ED/inpatient care was $18,891. CONCLUSIONS: Although comparison 
of societal costs is difficult given differences in methodology and years studied, 
societal costs increased from $8.6 billion in 2001 to over $55.7 billion in 2007. POMA 
is a societal problem and requires action by government, opioid manufacturers, 
practitioners and payers.
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OBJECTIVES: To investigate the demographic distribution and health care burden 
of patients diagnosed with ankylosing spondylitis (AS) using Medicare fee-for-
service (FFS) data. METHODS: A retrospective analysis was performed using the 
100% Medicare FFS Datasets from October 1, 2008 through December 31, 2012. 
Patients diagnosed with AS were identified using International Classification of 
Diseases, 9th Revision, Clinical Modification diagnosis code 720.0, and the first 
diagnosis date was designated as the index date. All patients were required to 
have continuous medical and pharmacy benefits 1-year pre- (baseline period) 
and post-index date (follow-up period). Health care resource utilization and costs 
during the baseline and follow-up periods were calculated. RESULTS: A total of 
8,990 AS patients were included in the study. The average age at diagnosis was 75 
years. Nearly 88.7% of patients were white, 62.97% were women and many resided 
in the South U.S. region (40.33%). The most common baseline comorbidities were 
chronic obstructive pulmonary disease (33.20%), diabetes (30.50%), cerebrovascular 
disease (22.65%) and congestive heart failure (18.85%). During the follow-up period, 
73.04% of patients had inpatient admissions, 52.31% had emergency room visits, 
91.43% had outpatient office visits, 91.43% had outpatient visits and 57.67% had 
pharmacy visits, resulting in average costs of, $37,077, $298, $5,397, $5,695 and 
$6,668, respectively. The average total costs were $49,440 during the follow-up 
period. The four most frequently prescribed medications for AS were prednisone 
hydrocodone (3.59%), bit/acetaminophen (3.17%), methotrexate sodium (2.79%) 
and levothyroxine sodium (2.42%). CONCLUSIONS: AS patient demographic and 
clinical characteristics in the Medicare population were assessed. Study patients 
were often diagnosed with comorbid conditions, and had high health care utili-
zation and costs.
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OBJECTIVES: Assess the timing of biologic initiation and associated healthcare uti-
lization and costs among psoriasis (PsO) patients. METHODS: Adults (18-64 years) 
with ≥ 2 PsO diagnoses (ICD-9-CM= 696.1) after 4/30/2004, ≥ 1 non-biologic pharma-
cologic systemic treatment (“non-biologic”) after the first observed diagnosis, and 
≥ 1 biologic treatment after the first non-biologic were selected from a de-identified 
US-based claims database. The index date was the date of the first biologic after 
the first non-biologic prescription fill. Patients had continuous eligibility during the 
12-months before (baseline) and 24-months following (study period) the index date. 
Patients were categorized into two cohorts based on days from the first non-biologic 
to index date: “> 180-days” and “≤ 180-days”. Study period utilization and costs were 
compared between cohorts using unadjusted and multivariable adjusted analy-
ses. RESULTS: There were 759 “> 180-days” and 881 “≤ 180-days” patients identified. 
During baseline, more patients in the“≤ 180-days” cohort had psoriatic arthritis 
compared to the “> 180-days” cohort (38.3% vs. 31.1%). “≤ 180-days” patients incurred 
more inpatients visits; higher medical, inpatient, and outpatient costs; and lower 
pharmacy costs compared to “> 180-days” patients during baseline. During the study 
period, the “≤ 180-days” cohort had higher unadjusted number of emergency room 
(0.52 vs 0.45) and outpatient visits (36.03 vs 31.89) as well as higher total ($20,971 vs 
$17,922, excluding PsO biologic costs), medical ($15,577 vs $12,749), and outpatient 
costs ($11,466 vs $9,527) (all p-values< 0.05). Multivariable regressions adjusting for 
baseline characteristics confirmed the unadjusted results. The numeric difference 
in adjusted costs between cohorts was small (adjusted 24-month difference in total, 
medical, and pharmacy costs= $3,123, $1,851 and $2,464, p-value= 0.0609, 0.0016, and 
0.2202, respectively). CONCLUSIONS: PsO patients initiating biologics ≤ 180-days 
from the first non-biologic had more severe disease and higher costs at baseline. 
Over the 24-month study period, differences in healthcare utilization and costs 
between patients with different timing of biologic initiation were small and not 
clinically meaningful.
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OBJECTIVES: Chron’s disease and ulcerative colitis are clinically similar diseases, 
classified as serious inflammatory diseases mainly in the intestinal region. A cost 
minimization analysis was conducted in order to compare the costs of treatment 
of infliximab versus adalimumab in the treatment of ulcerative colitis and Chron´s 
disease. METHODS: Considering published data on network meta-analysis provid-
ing similar results on the efficacy of both treatments, a cost-minimization analy-
sis was developed under the public and private healthcare system perspective . 
Comparator prices were obtained from public available sources (government cen-
tralized purchased contracts in the Public Perspective and factory prices including 
taxes (PF18%) in the Private Perspective). Annual costs were calculated according to 
the dose described on drugs’ respective labels. The average weight per patient was 
64 kg, based on the only local clinical study in Chron´s Disease patients reporting 
weight found in a literature review. RESULTS: Annual costs were divided between 
induction (1st year) and maintenance (2ndyear and so forth) regimens. Annual 
cumulative costs for induction regimen were R$ 24,041.98 and R$ 22,874.32 on 
the public perspective and R$ 80,527.36 and R$ 88,007.36 on private perspective 
for infliximab and adalimumab, respectively. Maintenance regimen costs were 
R$ 18,031.49 and R$ 19,606.56 on the public perspective and R$ 60,395.52 and R$ 
75,434.88 on the private perpective for infliximab and adalimumab, respectively. 
Incremental costs on a 2-year time horizon was -R$ 407.41, in the public perspec-
tive, and -R$ 22,519.36, in the private perspective (infliximab is less costly than 
adalimumab). CONCLUSIONS: In the public perspective, although showing higher 
costs on the first year of treatment, infliximab is less costly on longer treatment 
duration. On the private perspective, infliximab is less costly regardless of time 
horizon or treatment regimen.
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OBJECTIVES: To compare all-cause and thalassemia-related healthcare resource uti-
lization (RU) and costs in thalassemia patients who are adherent vs. non-adherent 
to iron chelation therapy (ICT). METHODS: Healthcare claims databases from six 
state Medicaid programs (Florida, Iowa, Kansas, Mississippi, Missouri, and New 
Jersey) (1997-2013) were analyzed. Patients with ≥ 1thalassemia ICD-9 diagnosis 
code, ≥ 2 dispensings for deferoxamine or deferasirox, and ≥ 6 months of continu-
ous enrollment before first ICT dispensing were included. Adherence was defined 
as a medication possession ratio ≥ 0.80. All-cause and thalassemia-related RU and 
costs were evaluated per-patient-per-month (PPPM) during the treatment period. 
Adherent and non-adherent patients were compared using adjusted incidence rate 
ratios (aIRR) for RU, and adjusted cost differences (aCD). RESULTS: Of the 218 eligible 
thalassemia patients, 137(62.8%) were adherent. Baseline demographic and clinical 
characteristics were similar between adherent and non-adherent patients, although 
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respectively (P< .05 vs placebo). CONCLUSIONS: These findings suggest that PHEN/
TPM ER-enhanced WL is associated with a reduction in annual medication costs vs 
placebo in patients with MetS.
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OBJECTIVES: Immunobiologicals (IMB) should only be used as a second line treatment 
of rheumatic diseases because of its potential risks and high cost. This study aimed 
to outline the profile of IMB use by the analyses of pharmacotherapeutic and phar-
macoeconomic indicators derived from a cohort of rheumatic patients. METHODS: 
This was a prospective observational exploratory study that analyzed data from the 
follow-up charts of 204 patients in treatment with IMB, previously authorized by rheu-
matologists and then monitored by a Pharmaceutical Auditing Clinical Management 
Program of a Health Insurance Provider in Fortaleza, Brazil, from March-2012 to 
September-2014. For the pharmacotherapeutic and economic analysis, the follow-
ing indicators were used: “Most used IMB” “ indication of the IMB therapy”, “route of 
administration” and “direct cost”. For calculation of the costs, the electronic source 
Brasíndice was used. RESULTS: The most common indications for IMB use were 
rheumatoid arthritis 46.57 % (95/204) and ankylosing spondylitis 41.67% (85/204). 
The intravenous route (IV) was more frequent, 63 % (158/251), when compared to the 
subcutaneous (SC), 37 % (93/251). The main IV IMB was infliximab, 37.27 % (81/251). 
The most used SC IMB and higher proportional increase prescriptive was adalimumab 
15.94% (40/251). The IMB with higher direct cost was infliximab, U$ 41,147.52 per 
capita. The cumulative global cost the immunobiological therapy during the period 
of study was U$6,366,673.33 as adjusted by weight. CONCLUSIONS: Monitoring of 
patients using IMB through a multidisciplinary team is an important clinical manage-
ment tool, enabling the development of strategies for the rationalization of future 
interventions and reduction of its high cost.
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OBJECTIVES: To quantify the clinical and economic benefits of weight loss among 
obese adults in the U.S. and how benefits vary across subsets of the obese popula-
tion. METHODS: A validated, Markov-based microsimulation model was used to sim-
ulate 10-year health and economic outcomes for different subsets of the obese adult 
population, with sample populations drawn from the 2005-2012 National Health and 
Nutrition Examination Surveys. Obese subgroups included those with prediabetes; 
ages 20-44, 45-64, and 65 and above; and obese category I, II, and III cohorts. Prediction 
equations for disease onset and economic outcomes come from published literature 
and original research. The model predicts direct and indirect economic outcomes 
from payer, employer, and societal perspectives. RESULTS: The present value (3% 
discount rate) of simulated medical savings associated with modest 5% weight among 
obese adults averaged $9,100 cumulative over 10 years. Obese adults age 65 and older 
and obese adults with prediabetes experienced the most medical savings—averaging 
$20,550 and $14,110, respectively, over 10 years. Simulated medical benefits among 
these cohorts came from reduced onset of cardiovascular disease, diabetes, and other 
chronic conditions associated with obesity. Subgroups with the lowest savings from 
5% weight loss were the age 20-44 and category I obese groups, averaging $5,800 and 
$7,290, respectively, over 10 years. Weight loss resulted in the largest reduction in dia-
betes incidence in the obese with prediabetes and obese age 20-44 populations, with 
10-year incidence reductions of 19% and 16%, respectively. CONCLUSIONS: Intensive 
lifestyle intervention and other weight loss programs often exceed 5% weight loss, 
generating sizeable medical savings that vary by patient characteristics. Study results 
underscore the importance of reducing excess body weight to prevent new onset of 
disease, and help identify target populations to maximize the medical savings and 
other benefits of weight loss.
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OBJECTIVES: Opioid induced constipation (OIC) is the most common, persistent 
and debilitating side effect reported in patients receiving opioids to manage pain. 
Laxatives are commonly prescribed to treat OIC but in some patients they provide 
inadequate response. Movantik is a peripherally acting mu-opioid receptor antago-
nist used to treat patients with inadequate response to laxative(s) (LIR). A cost effec-
tiveness model was constructed from the UK payer perspective to compare Movantik 
25mg with placebo, rescue laxatives, Relistor and Targin in LIR patients. METHODS: 
Two Phase III 12-week placebo-controlled RCTs, KODIAC 4 and 5, provided data on 
response rates, transition probabilities and EQ-5D inputs for the model for Movantik, 
placebo and rescue laxatives. Tolerability data in the model is generated from both 
these studies and KODIAC 8, a 52-week safety study. The model comprises a decision 
tree for the first 4 weeks of treatment, followed by a Markov model with a 4-week 
cycle length and the following states: non-OIC on treatment, OIC, non-OIC not on 
treatment and death. A mixed treatment comparison provides data on OIC status 
for Relistor and Targin. Resource utilization data used in the model were gathered 
from a UK-based burden of illness study and physician surveys. RESULTS: Movantik 
has an ICER of £10,849 vs. placebo, of £12,639 vs. placebo & rescue laxatives and is 
dominant vs Relistor over a 5 year time horizon in LIR patients. The probabilistic 
OBJECTIVES: To determine healthcare costs among immediate release (IR) hydroco-
done patients diagnosed with opioid abuse compared to those without such diagno-
sis in the United States (US). METHODS: Retrospective analysis using claims from 
the Truven MarketScan® commercial, Medicare supplemental, and Medicaid data-
bases was performed. Patients prescribed IR hydrocodone during the 6-month base-
line period (7/2011-12/2011), and with continuous enrollment during baseline and 
the 12-month follow-up period (2012), were selected. IR hydrocodone patients with 
an ICD-9-CM diagnosis for opioid abuse or dependence (abuse) were identified in 
the follow-up period. Descriptive analyses were employed to compare demographic 
and clinical characteristics between diagnosed opioid abusers and non-abusers. 
Total healthcare costs (standardized to 2013 US dollars) for abusers vs. non-abusers 
during the follow-up were estimated by plan type. Propensity score matching was 
used to estimate incremental costs in the follow-up. RESULTS: A total of 1,743,933 
commercial, 277,096 Medicare, and 157,992 Medicaid IR hydrocodone patients were 
selected. Prevalence of diagnosed opioid abuse for these samples in follow-up was 
0.9%, 0.5%, and 3.2% for commercial, Medicare, and Medicaid, respectively. Among 
commercial patients, unmatched data at baseline showed that abusers had on aver-
age higher co-morbidity burden (0.96 vs. 0.67), and higher pill count (60.8 vs. 20.5 
pills/month) and days’ supply (67.4 vs. 24.1 days) for IR hydrocodone, compared to 
non-abusers. After matching there were no differences in co-morbidity burden (.96 
vs. .99) and pill count (60.8 vs. 60.5) but days’ supply remained significantly different 
(67.4 vs. 63.4). In the matched subset, incremental costs were significantly higher 
among abusers ($14,720, $6,589, and $14,786 for commercial, Medicare, and Medicaid 
patients, respectively) as compared with non-abusers. CONCLUSIONS: IR hydroco-
done patients with diagnosed opioid abuse have higher healthcare costs when com-
pared to matched non-abusers, suggesting significant negative economic impact 
of opioid abuse in the US. Similar trends were observed regardless of plan type.
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OBJECTIVES: Studies have estimated the cost of biologics needed to achieve an addi-
tional responder as measured by Psoriasis Area and Severity Index (PASI) 75and PASI 
90; however, limited information is available including PASI 100. The purpose of this 
analysis was to evaluate the cost per additional responder associated with biologics 
for PASI 75, PASI 90 and PASI 100. METHODS: A literature review was conducted to 
identify randomized controlled trials and meta-analyses that included informa-
tion on PASI 75, PASI 90 or PASI 100 and associated number needed to treat (NNT) 
compared to placebo for adalimumab (ADA), etanercept (ETN), infliximab (IFX), and 
ustekinumab (UST). NNT was calculated as the inverse of absolute risk reduction 
from placebo. The Wholesale Acquisition Costs for each biologic incurred during 
12 weeks of treatment from initiation were determined using Analy$ource® data 
as of November 2014. Administration costs were not included. Cost per additional 
responder was calculated as the NNT multiplied by 12 week drug costs. RESULTS: 
Cost per additional responder for PASI 75 was lowest for ADA ($18,065 - $18,647) 
and IFX ($18,101 - $19,493) followed by UST 45mg ($23,903 - $24,516), ETN ($37,825 
- $41,036), and UST 90mg ($45,048 - $48,418). Cost per additional responder for PASI 
90 was lowest for ADA ($26,805 – $30,418) and IFX ($27,569 - $30,632) followed by UST 
45mg ($38,765 - $39,532), UST 90mg ($71,095 - $88,256) and ETN ($84,749 - $89,209). 
Limited data were available on PASI 100; however, cost per additional responder was 
found to be higher than PASI 75 and PASI 90 based on available data. CONCLUSIONS: 
Cost per additional responder was higher for PASI 90 and PASI 100 given the greater 
NNT for each measure respectively. Understanding the association between costs 
and NNT across various levels of efficacy may be valuable for decision makers when 
evaluating multiple medications.
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OBJECTIVES: Higher healthcare costs are incurred by patients with MetS. WL may 
decrease the risk of MetS and its component comorbidities, thereby reducing medi-
cation use. PHEN/TPM ER treatment, combined with lifestyle interventions, can 
induce WL and reduce incidence of MetS. This post-hoc analysis of a PHEN/TPM ER 
study evaluated annual cost-offsets associated with changes in concomitant medi-
cation use among patients with MetS. METHODS: CONQUER randomized obese/
overweight patients (BMI ≥ 27 -≤ 45kg/m2) with ≥ 2 weight-related comorbidities to 
placebo (n= 994), PHEN 7.5mg/TPM ER 46mg (7.5/46; n= 498), or PHEN 15mg/TPM ER 
92mg (15/92; n= 995). MetS was defined as presence of ≥ 3 of the following risk fac-
tors: waist circumference ≥ 102cm (men), ≥ 88cm (women); triglycerides ≥ 150mg/dL; 
HDL-cholesterol < 40mg/dL (men), < 50mgl/dL (women); systolic blood pressure (BP) 
≥ 130mmHg or diastolic BP ≥ 85mmHg; and fasting glucose ≥ 100mg/dL. This analysis 
included patients with MetS using ≥ 1 concomitant medication at baseline or end of 
treatment (EOT) for hypertension, dyslipidemia, or type 2 diabetes. Cost-offsets (±SD) 
in antihypertensive, lipid-lowering, and antidiabetic medication use were calculated 
by multiplying unit cost (Medi-Span’s PriceRx) by number of doses per day from 
baseline to Week 56/EOT. PHEN/TPM ER cost was not included. RESULTS: In total, 349 
patients receiving placebo, 184 receiving 7.5/46, and 359 receiving 15/92, had MetS at 
baseline and received ≥ 1 concomitant medication. At baseline, mean weight (±SD) 
was 105±18kg among all patients. Baseline annual concomitant medication costs 
were $1222±1450, $1306±1401, and $1303±1348 for placebo, 7.5/46, and 15/92, respec-
tively. At EOT, mean percent WL was -1.9%, -8.6%, and -10.5%, respectively (P< .0001 
vs placebo). At EOT, annual concomitant medication costs increased with placebo 
and decreased with PHEN/TPM ER: $36±33 (+3%), -$83±46 (-6%), and -$103±33 (-8%), 
